Add to ORKGUsing a prospective, randomized, blinded, placebo-controlled protocol, the authors demonstrated that Cerebrolysin at doses of 0.8-7.5 ml/kg, administered 4 hours after injury and then once daily for a total of 10 consecutive days, improves long-term functional outcomes in a rat model of mild closed head injury; a 2.5-ml/kg dose was identified as optimal. These findings suggest that Cerebrolysin has the potential to treat mild traumatic brain injury, the incidence of which is high without effective treatments
Cerebrolysin (CBL) is a neuroprotective agent in central nervous system (CNS) injury and stimulates ...
Stroke is still a significant health problem that affects millions of people worldwide, as it is the...
BACKGROUND: The goal of the study was to evaluate the effects of Cl-inhibitor (C1-INH), an endogenou...
Using a prospective, randomized, blinded, placebo-controlled protocol, the authors demonstrated that...
Background and aims: Our previous study identified an optimal dose of Cerebrolysin as 2.5ml/kg for t...
BACKGROUND: Cerebrolysin is a neuropeptide preparation with neuroprotective and neurotrophic propert...
OBJECTIVE: The authors previously demonstrated that Cerebrolysin is effective for treatment of mild ...
BACKGROUND: Cerebrolysin is a mixture of neuropeptides and free amino acids that is clinically used ...
OBJECT: Long-term memory deficits occur after mild traumatic brain injuries (mTBIs), and effective t...
Background and aims In an effort to characterize the effects of Cerebrolysin for treatment of stroke...
Background: Traumatic brain injury (TBI) remains a main public health problem being associated with ...
Background. The most important task of intensive care patients with traumatic brain injury is preven...
BACKGROUND: Our previous work in acute ischemic stroke and TBI models focused on efficacy and pharma...
Cerebrolysin is the only drug available for clinical use containing active fragments of some importa...
Abstract Background Spinal cord injury (SCI) is widely considered the most disastrous medical condit...
Cerebrolysin (CBL) is a neuroprotective agent in central nervous system (CNS) injury and stimulates ...
Stroke is still a significant health problem that affects millions of people worldwide, as it is the...
BACKGROUND: The goal of the study was to evaluate the effects of Cl-inhibitor (C1-INH), an endogenou...
Using a prospective, randomized, blinded, placebo-controlled protocol, the authors demonstrated that...
Background and aims: Our previous study identified an optimal dose of Cerebrolysin as 2.5ml/kg for t...
BACKGROUND: Cerebrolysin is a neuropeptide preparation with neuroprotective and neurotrophic propert...
OBJECTIVE: The authors previously demonstrated that Cerebrolysin is effective for treatment of mild ...
BACKGROUND: Cerebrolysin is a mixture of neuropeptides and free amino acids that is clinically used ...
OBJECT: Long-term memory deficits occur after mild traumatic brain injuries (mTBIs), and effective t...
Background and aims In an effort to characterize the effects of Cerebrolysin for treatment of stroke...
Background: Traumatic brain injury (TBI) remains a main public health problem being associated with ...
Background. The most important task of intensive care patients with traumatic brain injury is preven...
BACKGROUND: Our previous work in acute ischemic stroke and TBI models focused on efficacy and pharma...
Cerebrolysin is the only drug available for clinical use containing active fragments of some importa...
Abstract Background Spinal cord injury (SCI) is widely considered the most disastrous medical condit...
Cerebrolysin (CBL) is a neuroprotective agent in central nervous system (CNS) injury and stimulates ...
Stroke is still a significant health problem that affects millions of people worldwide, as it is the...
BACKGROUND: The goal of the study was to evaluate the effects of Cl-inhibitor (C1-INH), an endogenou...
